Drug eluting stents in acute myocardial infarction

Panminerva Medica

Volumn 47, Issue 2, 2005, Pages 93-97

  Presbitero, P ^a   Boccuzzi, G ^a   Pagnotta, P ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Acute myocardial infarction; Drug eluting stent; Paclitaxel; Sirolimus

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; PACLITAXEL; RAPAMYCIN;

DRUG DELIVERY SYSTEM; HEART INFARCTION; HUMAN; REVIEW; STENT; THROMBOSIS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL INFARCTION; PACLITAXEL; SIROLIMUS; STENTS; THROMBOSIS;

EID: 27744444505     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Ribichini F, Ferrero V, Wijns W. Reperfusion treatment of ST-elevation acute myocardial infarction. Progr Cardiovasc Dis 2004;47:131-57.
2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
3. Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341:1413-9.
4. Nunn CM, O'Neill WW, Rothbaum D, Stone GW, O'Keefe J, Overlie P et al. Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. J Am Coll Cardiol 1999;33:640-6.
5. Grines CL, Serruys P, O'Neill WW. Fibrinolytic therapy: is it a treatment of the past? Circulation 2003;107:2538-42.
6. Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 2001;88:297-301.
7. Halkin A, Aymong E, Cox DA, Mehran R, Lansky AJ, Fahy M et al. Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC Trial). Am J Cardiol 2004;93:349-53.
8. Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J et al. Effect of glycoprotein receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-21.
9. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
10. Babinska A, Markell MS, Salifu MO, Akoad M, Ehrlich YH, Kornecki E. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 1998;13:3153-9.
11. Cullip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent trials. Circulation 2001;103:1967-71.
12. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabatè M et al. Drug eluting stent thrombosis. Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45: 954-9.
13. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al., SIRIUS investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
14. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E et al. E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
15. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM et al., C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5.
16. Mintz GS, Tinana A, Hong MK, Lee CW, Kim JJ, Fearnot NE et al. Impact of preinterventional arterial remodeling on neointimal hyperplasia after implantation of (non-polymer-encapsulated) paclitaxel-coated: a serial volumetric intravascular ultrasound analysis fro the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 2003;108:1295-8.
17. Gerslick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaluation of paclitaxel Eluting Stent (ELUTES) trial. Circulation 2004;109: 487-93.
18. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerskens U et al. TAXUS I: six and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
19. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S et al. TAXUS II Study Group Randomized study to assess the effectiveness of slow and moderate release polymer-based paclitaxel-eluting stents for coronary lesions. Circulation 2003;108:788-94.
20. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
21. Lansky A, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA et al. for the DELIVER Clinical Trial Investigators. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions. Angiographic follow-up of the DELIVER Clinical Trial. Circulation 2004;109:1948-54.
22. Ong ATL, Hoye A, Aoki J, Van Mieghem CAG, Rodriguez Granillo GA, Sonnenschein K et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-53.
23. Morice MC, Serruys P, Colombo P, Meier B, Tamburino C, Guagliumi G et al. Eight-month outcome of the Reality Study: a prospective randomized multi-center head-to-head comparison of sirolimus-eluting stent (Cypher) and the paclitaxel-eluting stent (Taxus). Proceedings of the Annual Scientific Session of the American College of Cardiology, 2005, March 6-9, Orlando, FL
24. Cheneau E, Leborgne L, Mintz GE. Predictors of subacute stent thrombosis. Results of a systematic ultrasound study. Circulation 2003;108:43-7.
25. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT et al.; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
26. Spanos V, Vitrella G, Colombo A. Using intravascular ultrasound with drug-eluting stents. What have we learned so far? Minerva Cardioangiol 2003;51:493-505, 505-11. English, Italian.
27. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V et al. Randomized study to evaluate sirolimus-eluting stents implated at coronary bifurcation lesions. Circulation 2004;109:1244-9. Epub 2004 Feb 23.
28. Lev EI, Assali AR, Teplisky I, Rechavia E, Hasdai D, Sela O et al. Comparison of outcomes up to six months of heparin-coated with noncoated stents after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2004;93:741-3.
29. Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA et al. Short and long term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004;43:704-8.
30. Saia F, Lemos PA, Lee C, Arampatzis CA, Hoye A, Degertekin M et al. Sirolimus-Eluting Stent Implantation in ST-Elevation Acute Myocardial Infarction. A Clinical and Angiographic Study. Circulation 2003;108:1927-9.
31. Menichelli M, Parma A, Fiorilli R. Randomised study of drug-eluting stent (sirolimus) vs conventional stent in acute myocardial infarction treated with primary angioplasty: preliminary results. Eur Heart J 2004;416.
32. Gershlick AH, Lotan C, Urban P. Treatment of acute myocardial infarction with sirolimus eluting coronary stents: midterm results from the e-Cypher international registry. Am J Cardiol 2004;94:11E.
33. Katz S, Costa MA, Berger PB, Reynolds L, Keim E, Cohen S et al. The Cypher US Post market surveillance registry (e-Cypher)- six months results in acute myocardial infarction patients. J Am Coll Cardiol 2005;95:866A.
34. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary interventions? A meta-analysis. J Am Coll Cardiol 2005;45:941-6.
35. Ong ATL, Hoye A, Aoki J. Paclitaxel-eluting stent implantation in an unselected consecutive cohort of patients with de novo lesions: medium term results from the T-SEARCH registry. Eur Heart J 2004;26:94A.
36. Dharmadhikari A, Chopada M, Tzifos V, Sheiban I, Airoldi F, Panagakos E et al. Drug eluting stents should be used judiciously in acute myocardial infarction. Eur Heart J 2004;26:523A.
37. Margheri M, Giglioli C, Comeglio M, Valente S, Chechi T, Falai M et al. Early outcome paclitaxel-eluting stents in patients with acute and subacute myocardial infarction. A clinical study. Ital Heart J 2004;5:536-40.
38. Kastrati A, Dibra A, Mehilli J, Pache J, Schühlen H, von Beckerath N et al. Paclitaxel-eluting stent versus sirolimus-eluting stent for the prevention of restenosis in diabetic patients with coronary artery disease. Proceedings of the Annual Scientific Session of the American College of Cardiology, 2005, March 6-9, Orlando, FL.